The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The Hyderabad Public School Society celebrates Dr Rao’s journey from HPS Ramanthapur to becoming one of India's leading medical professionals
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
For the full year, standalone gross revenue crossed Rs. 1,700 crore
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
The new facility marks Align’s first manufacturing presence in India and its fourth globally
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
